OM Outset Medical, Inc.

company

SEC Filings & Insider Trading Activity 2026

Business Overview

• • Core business model not detailed; focus on corporate governance and compliance policies
• • No new products, services, or segments introduced or emphasized this year
• • No strategic shift or changed competitive positioning disclosed in this filing
• • Independent registered public accounting firm named as KPMG LLP, Auditor ID: 185
• • Business section mainly references governance codes and proxy statement disclosures for fiscal 2026

Risk Factors

• • FDA warning letter in 2023 and ongoing compliance risks with medical device regulations impacting Tablo production and approval processes
• • Dependence on Mexico manufacturing exposed to U.S. tariffs risk from Section 232 Trade Expansion Act investigation started September 2025
• • Reliance on third-party suppliers and insourced Mexican manufacturing with potential supply chain disruption from labor disputes or public health crises
• • Competition from dominant home dialysis providers DaVita and Fresenius challenging Tablo's market penetration in home and post-acute care
• • Revenue concentrated in Tablo product with customer financial pressures from rising interest rates and budget constraints elongating sales cycles since 2023

Management Discussion & Analysis

• • Revenue $119.5M, up 5% YoY from $113.7M; product revenue $84.8M (+5%), service revenue $34.7M (+6%)
• • Gross margin 39.1% vs 33.9%, gross profit $46.8M, up 21%, driven by higher console and consumable margins
• • Best segment: Consumables revenue up $2.9M, console revenue up $0.9M; worst: overall sales down from 2023, console sales portion declined
• • Operating expenses down 25% to $113.5M from $151.9M, driven by cuts in R&D (-45%), sales and marketing (-22%), general and admin (-13%)
• • No explicit cash flow, buyback or dividend data disclosed; noted cost reduction and efficiency efforts ongoing
• • Forward outlook risks: macroeconomic pressure, tariffs, rising costs, cautious customer capital spending delaying sales; focus on expanding acute and home dialysis markets

What are the latest OM SEC filings in 2026?

Outset Medical, Inc. (OM) has filed a 10-K annual report on February 13, 2026, a 10-Q quarterly report on May 7, 2026, an 8-K current report on June 17, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.

When did OM file its most recent 10-K annual report?

Outset Medical, Inc. (OM) filed its most recent 10-K annual report on February 13, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.

How do I view OM 10-Q quarterly reports?

Outset Medical, Inc. (OM)'s most recent 10-Q quarterly report was filed on May 7, 2026. SignalX displays every OM 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.

What 8-K current reports has OM filed recently?

Outset Medical, Inc. (OM)'s most recent 8-K was filed on June 17, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.

Where can I find OM insider trading activity (Form 4)?

SignalX aggregates every OM Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.

How often does OM file with the SEC?

Outset Medical, Inc. (OM) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new OM filing with AI-powered analysis.

What is the difference between 10-K, 10-Q, and 8-K SEC filings?

A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs, such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Outset Medical, Inc. (OM).

What is OM's SEC CIK number?

Outset Medical, Inc. (OM)'s SEC CIK (Central Index Key) number is 1484612. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1484612 to look up all OM filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.

Where can I find OM return on equity (ROE) and financial data?

SignalX extracts XBRL financial data from Outset Medical, Inc. (OM) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.